Suzuken Co., Ltd.

9987.T
Medical Distribution
2026/02/16 Updated
Market Cap: $2.8B (¥427.6B)
Stock Price: $40.81 (¥6,240)
Exchange Rate: 1 USD = ¥152.91

Notice Regarding Intra-Group Organizational Restructuring (Simplified Incorporation-type Company Split and Simplified Absorption-type Company Split)

On April 1, 2026, the manufacturer logistics contract business of consolidated subsidiary SD Collabo will be transferred by a simplified incorporation-type company split to the newly established company Collabo Create. Simultaneously, assets related to the manufacturer logistics contract business of SD Logi will be transferred by absorption-type company split to Suzuken, implementing an organizational restructuring.

Importance:
Page Updated: February 12, 2026
IR Disclosure Date: February 12, 2026

Key Figures

  • Sales of business transferred by incorporation-type company split: 13,813 million yen (Fiscal Year ended March 2025)
  • Assets transferred by incorporation-type company split: 50 million yen (As of March 31, 2025)
  • Assets transferred by absorption-type company split: 17,274 million yen, Liabilities: 14,468 million yen (As of March 31, 2025)

AI要約

Overview of Organizational Restructuring

Suzuken Co., Ltd. resolved to execute a simplified incorporation-type company split effective April 1, 2026, transferring the manufacturer logistics contract business of consolidated subsidiary SD Collabo to the newly established company Collabo Create. As a result, SD Collabo will specialize in the specialty pharmaceuticals distribution contract business, while the new company will handle the manufacturer logistics contract business. Additionally, assets related to the manufacturer logistics contract business of consolidated subsidiary SD Logi will be transferred to Suzuken through an absorption-type company split, aiming to enhance logistics efficiency and human resource development across the group.

Outlook and Impact

This organizational restructuring involves a company split between wholly-owned subsidiaries, with effective dates of March 31 and April 1, 2026. Based on the sales and profit levels for the fiscal year ended March 2025, the impact on consolidated results for the current term is expected to be minor. The newly established Collabo Create will focus on specialized fields and engage in solving social issues through investment and personnel exchanges with partner companies.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.